How are VTRS strangle max profit and max loss calculated?

Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the VTRS strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 32.40%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$135.00 per contract. Live intraday quotes will differ as the chain moves through the trading session.

What is the breakeven for a VTRS strangle?

The breakeven for the VTRS strangle priced on this page is roughly $14.65 and $18.35 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current VTRS market-implied 1-standard-deviation expected move is approximately 9.29%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.

How does current VTRS implied volatility affect this strangle?

VTRS ATM IV is at 32.40% with IV rank near 3.30%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.

VTRS Strangle Strategy

VTRS (Viatris Inc.), in the Healthcare sector, (Drug Manufacturers - Specialty & Generic industry), listed on NASDAQ.

Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides its medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies.

VTRS (Viatris Inc.) trades in the Healthcare sector, specifically Drug Manufacturers - Specialty & Generic, with a market capitalization of approximately $20.23B, a beta of 0.87 versus the broader market, a 52-week range of 8.19-17.53, average daily share volume of 11.3M, a public-listing history dating back to 1980, approximately 32K full-time employees. These structural characteristics shape how VTRS stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 0.87 places VTRS roughly in line with broader market moves, so the strategy payoff and realized volatility track the index-equivalent baseline. VTRS pays a dividend, which adjusts put-call parity and shifts the ex-dividend pricing across the listed chain.

What is a strangle on VTRS?

A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.

Current VTRS snapshot

As of May 15, 2026, spot at $16.54, ATM IV 32.40%, IV rank 3.30%, expected move 9.29%. The strangle on VTRS below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 63-day expiry.

Why this strangle structure on VTRS specifically: VTRS IV at 32.40% is on the cheap side of its 1-year range, which favors premium-buying structures like a VTRS strangle, with a market-implied 1-standard-deviation move of approximately 9.29% (roughly $1.54 on the underlying). The 63-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated VTRS expiries trade a higher absolute premium for lower per-day decay. Position sizing on VTRS should anchor to the underlying notional of $16.54 per share and to the trader's directional view on VTRS stock.

VTRS strangle setup

The VTRS strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With VTRS near $16.54, the first option leg uses a $17.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed VTRS chain at a 63-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 VTRS shares for the stock leg in covered calls and collars).

Action	Type	Strike / Basis	Premium (est)
Buy 1	Call	$17.00	$0.70
Buy 1	Put	$16.00	$0.65

VTRS strangle risk and reward

Net Premium / Debit: -$135.00
Max Profit (per contract): Unbounded
Max Loss (per contract): -$135.00
Breakeven(s): $14.65, $18.35
Risk / Reward Ratio: Unbounded

Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.

VTRS strangle payoff curve

Modeled P&L at expiration across a range of underlying prices for the strangle on VTRS. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

Underlying Price	% From Spot	P&L at Expiration
$0.01	-99.9%	+$1,464.00
$3.67	-77.8%	+$1,098.40
$7.32	-55.7%	+$732.80
$10.98	-33.6%	+$367.21
$14.63	-11.5%	+$1.61
$18.29	+10.6%	-$6.01
$21.95	+32.7%	+$359.59
$25.60	+54.8%	+$725.19
$29.26	+76.9%	+$1,090.78
$32.91	+99.0%	+$1,456.38

When traders use strangle on VTRS

Strangles on VTRS are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the VTRS chain.

VTRS thesis for this strangle

The market-implied 1-standard-deviation range for VTRS extends from approximately $15.00 on the downside to $18.08 on the upside. A VTRS long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current VTRS IV rank near 3.30% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on VTRS at 32.40%. As a Healthcare name, VTRS options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to VTRS-specific events.

VTRS strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. VTRS positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move VTRS alongside the broader basket even when VTRS-specific fundamentals are unchanged. Always rebuild the position from current VTRS chain quotes before placing a trade.

Frequently asked questions

What is a strangle on VTRS?: A strangle on VTRS is the strangle strategy applied to VTRS (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With VTRS stock trading near $16.54, the strikes shown on this page are snapped to the nearest listed VTRS chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
How are VTRS strangle max profit and max loss calculated?: Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the VTRS strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 32.40%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$135.00 per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a VTRS strangle?: The breakeven for the VTRS strangle priced on this page is roughly $14.65 and $18.35 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current VTRS market-implied 1-standard-deviation expected move is approximately 9.29%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a strangle on VTRS?: Strangles on VTRS are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the VTRS chain.
How does current VTRS implied volatility affect this strangle?: VTRS ATM IV is at 32.40% with IV rank near 3.30%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.